Sanchez-Paulete et al. [38] reported that because of the lack of cross-presentation activation of tumor antigens and new antigens associated CTLs to participate in immune response, immune regulation monoclonal antibodies lost their enhanced immunotherapeutic effects on tumor therapy in Batf3−/− mice. This evidence concerns the gene BATF3 and neoplasm.